CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 12, 2014--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage
biopharmaceutical company developing a novel therapeutic approach for
the treatment of autoimmune diseases and genetically defined forms of
B-cell lymphoma, today announced that Baker Brothers Investments’ Julian
C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors,
effective March 10, 2014. Founded in 2000, Baker Brothers Investments
manages long-term investment funds focused on publicly traded life
sciences companies, for major university endowments and foundations.
“I would like to welcome Julian and Kelvin to the Board. Idera will
benefit immensely from their deep insights on successful clinical
development and experience working with many companies to bring novel
therapies to market,” said Jim Geraghty, Chairman of Idera’s Board of
Directors. “With this and other recent additions to our Board, we are
stronger than ever before, with the right balance of expertise needed to
support the Company’s mission of bringing important therapies for unmet
medical needs and orphan indications to patients as rapidly as possible.”
Julian C. Baker is a Managing Partner of Baker Brothers Investments. Mr.
Baker is currently a Director of Genomic Health, Inc. and Incyte
Corporation, Inc.Kelvin M. Neu, M.D., is a Managing Director of Baker
Brothers Investments. A physician, Dr. Neu also serves as a Director of
XOMA Corporation and Presidio Pharmaceuticals, Inc.
About Idera Pharmaceuticals, Inc.
Idera’s proprietary technology involves creating novel nucleic acid
therapeutics designed to inhibit over-activation of Toll-like Receptors
(TLRs). Idera is developing these therapeutics for the treatment of
genetically defined forms of B-cell lymphoma and for autoimmune diseases
with orphan indications. In addition to its TLR programs, Idera is
developing gene silencing oligonucleotides that it has created using its
proprietary technology, to inhibit the production of disease-associated
proteins by targeting RNA.
Source: Idera Pharmaceuticals, Inc.
Investor Contact:
Stern Investor Relations, Inc.
Sarah
McCabe, 267-909-9237
sarah@sternir.com
